NewYorkBIO Board of Directors


Peter G. Robinson, MPH
Chairman of the Board

Mr. Robinson is the Vice President and Chief Operating Officer of the University of Rochester Medical Center and Vice President, Government and Community Relations for the University. He has responsibility for the University’s role in economic development and is a member of the Finger Lakes Regional Economic Development Council. He is a voting member of the New York State Public Health & Health Planning Council, the Chairman of the Boards of High Technology of Rochester, Inc. (HTR) and Excell Partners, Inc., as well as Chairman of the Board for NewYorkBIO. He previously served as Chairman of the Greater Rochester Enterprise (GRE), and he also serves on the boards of several private and public community agencies. He earned his bachelor’s degree from the City College of New York and Master’s degrees from the New School for Social Research and Columbia University.


Cynthia Green, PhD, MBA
Executive Committee, Secretary

Cyndi Green is a Senior Director in Worldwide Business Development at Pfizer with responsibility for anti-infectives and vaccines. Cyndi joined Pfizer NYHQ in 2003 as Associate Director of Operations in Licensing and Development and has broad biotech and pharma experience in business development, strategy, venture capital and consulting. Currently, Cyndi has responsibility for partnering marketed and clinical stage assets, technologies, diagnostics, research platforms and patents. Cyndi played an integral role in the formation of RGo Biosciences (previously a resident in The Pfizer Incubator), led diligence activities for the formation of the Pfizer-GSK HIV joint venture (ViiV Healthcare), and has led/co-led a multitude of licensing assessments and divestitures over the years.


Donald Mazzullo, Esq.
Executive Committee, General and Legislative Counsel

Mr. Mazzullo is Partner at Harter Secrest and Emory and has represented a wide range of companies, not-for-profits, and associations in the state capital for twenty-three years. He started the government affairs practice group at Harter Secrest & Emery in 1984, and under his leadership, it has become an effective and respected lobbying firm. During that time, he has developed relationships with legislators on both sides of the aisle, has worked with several administrations, and has navigated numerous leadership changes in the Legislature.Mr. Mazzullo has represented a variety of clients in many industry sectors, including the New York State Restaurant Association, New York Biotechnology Association, GlaxoSmithKline, Delta Air Lines, Emerging Industries Alliance of New York State, New York State Chiropractic Association, Association of Safety Group Managers, Genesee & Wyoming Railroad, Amalgamated Transit Union, New York State Telecommunications Association, DaimlerChrysler Corporation, Cold Spring Harbor Laboratory, Genencor (A Danisco Company), OSI Pharmaceuticals, New York Hall of Science, and New York State Clinical Laboratory Association, together with numerous other private corporations and municipal, civic, and charitable organizations.


Robert Van Nostrand
Executive Committee, Treasurer

Bob Van Nostrand has been associated with NewYorkBIO for more than two decades. He was CFO of OSI Pharmaceuticals for over 20 years, helping to grow the company from an early phase to a major acquisition target. He has also been CFO of Aureon and is a member of the Board of Directors of Achillion.



Jane Wasman
Executive Committee, At-Large

Ms. Wasman is a strategic leader with 20+ years in the biopharma industry and extensive U.S. and international experience. An adaptable executive, she has achieved success in a range of settings, from large, public multinational companies to privately held start-up companies. Her expertise includes M&A, strategic development, corporate governance, international, litigation, commercial, compliance and government affairs, as well as operational implementation. As President, International, General Counsel and Chief, Strategic Development at Acorda Therapeutics, Ms. Wasman leads long-range planning and development in addition to international expansion. In this role, she collaborates with senior leadership on commercialization, licensing/M&A strategy and implementation, investor relations, product pipeline development and government affairs activities. She also built and manages Acorda’s legal, compliance, IP and quality functions. Her department was recognized as one of four "Best Legal Departments" nationally by Corporate Counsel in 2013. Ms. Wasman played a central role in Acorda’s IPO and transition from a private, development stage entity to a public, commercial company. Additionally, she led the legal process for two key acquisitions - the $525M acquisition of Civitas Therapeutics and the first-ever acquisition of a dual stock exchange-listed Finnish company, Biotie Therapies, in a $400M transaction. She also helped build Acorda’s corporate governance/board infrastructure, and works closely with the board of directors on strategic, operational and governance matters. Prior to her 13 years at Acorda, Ms. Wasman spent over eight years at Schering-Plough Corporation in various leadership positions – including Staff Vice President and Associate General Counsel as well as Staff Vice President, European Operations – Legal and litigation & regulatory roles – that supported commercial, international, regulatory, licensing/M&A and global R&D activities. She was based in Europe for three years, establishing and running the company’s European legal office. Previously, Ms. Wasman was an attorney at two global law firms and Associate Counsel for the U.S. Senate Veterans’ Affairs Committee. Her early career provided broad industry experience, including industrial, financial, real estate and communications. Ms. Wasman has served since 2007 on the non-profit Board of Directors of NewYork BIO, including its Executive Committee and Public Policy Committee (Chair). She is also on the General Counsel Executive Committee of the Biotechnology Innovation Organization (BIO). Ms. Wasman graduated magna cum laude from Princeton University, and earned her J.D. from Harvard Law School. She currently resides in New York City.


Michael Aberman

Michael Aberman, M.D. is president and chief executive officer of Quentis Therapeutics. Prior to joining Quentis, Dr. Aberman spent over seven years at Regeneron Pharmaceuticals as the Senior Vice President of Investor Relations and Strategy. In that role, Dr. Aberman was a member of the senior management team and was responsible for the investor relations, corporate communications, business development, and corporate strategy functions at Regeneron. Prior to joining Regeneron, Dr. Aberman spent six years as a Wall Street research analyst covering the biotechnology industry at Credit Suisse and Morgan Stanley. Before moving to Wall Street, Dr. Aberman was Director of Business Development at Antigenics, Inc., an oncology-focused biotechnology company. Dr. Aberman received his B.A. from Cornell University and his medical degree from the University of Toronto. He completed his residency training at New York Presbyterian Hospital and received an M.B.A. from The Wharton School of Business.


Annette Bakker

Annette Bakker, the Children's Tumor Foundation's President and Chief Scientific Officer, holds a PhD in cell biology from the University of Antwerp. Her past experience includes serving as Oncology Group Leader at Janssen Pharmaceutica, and postdoctoral fellowships at Yale University and La Salpetriere, Paris. Before joining the Children’s Tumor Foundation, Dr. Bakker served as head of the Oncology R&D department for a biotech company in Siena, Tuscany. While there, she designed and created a neuro-oncology department from the ground up, and managed large oncology research initiatives both nationally (Italian networks) and internationally (European and Asian networks). Dr. Bakker's research has been internationally recognized by more than 30 peer-reviewed papers, patents, and awards, and she has extensive experience liaising and negotiating with biotechnology and pharmaceutical companies. In her role at the Children's Tumor Foundation, Annette and her team will continue to build a strong NF community, design and execute innovative business models to accelerate the path from basic discovery to clinical benefit for NF patients, develop partnerships with pharmaceutical and biotech industries, and attract new scientists and funders to the NF field. Annette is originally from Belgium, and speaks four languages (English, French, Dutch, and Italian). She lives happily in Westchester, NY with her family.


Greg Blyskal

Greg Blyskal is the Executive Director of Broad Hollow Bioscience Park.  He has worked in the bioscience field for over 30 years. Greg has a medical biology degree and an MBA in marketing with a minor in finance.  He began his business career with a division of American Home Products and worked as a Product Manager in its medical diagnostic division.  In 1987 he joined a start-up European biotech company, Dynal, with a leading product line in cell and protein magnetic separation.  Greg was President of the U.S. subsidiary from 1989 to 2000, prior to the company being sold to Invitrogen for  €300 million. Greg joined Broad Hollow Bioscience Park (BHBP), an economic development program to support early-stage bioscience companies, as the Executive Director in 2000 the year it opened its first facility on the campus of Farmingdale State College.  BHBP is a collaboration between the State University of New York (SUNY) and Cold Spring Harbor Laboratory. In 2002 OSI Pharmaceuticals became the program’s anchor tenant and in 2008 BHBP opened its second facility.  In 2011 the lease agreement with OSI was expanded with OSI’s new owner Astellas Pharma, however, a global restructuring by Astellas resulted in a 2014 buy-out of the lease agreement.  In recent years, BHBP has recruited six new companies and is in the process of repurposing the original anchor facility with the goal of developing collaborative activities with the  college’s sciences departments. BHBP is an integral part of the Long Island Regional Economic Development Council’s goal to expand biotech and foster the growth and development of well-paying industries for New York.


Dan Brettler

Dan is Managing Director, Senior Vice President, Life Science and Technology Practice Leader at Conner Strong and Buckelew where he is responsible for all aspects of risk management & insurance products and services delivered to Life Science & Technology clients of Conner Strong & Buckelew. In addition, he has management responsibilities for growing the practice within the strategic plan of the overall insurance brokerage. Brettler has 20 years of solid risk management & insurance experience, the majority of which has been devoted exclusively to the Life Science & Technology industries. Specific areas of insurance expertise include on a global basis Products Liability, Human Clinical Trials, Directors’ & Officers’ Liability and Property Coverage for GMP facilities.


Richard Catalano

Richard A. Catalano is an audit partner in KPMG’s Metro New York business unit. Mr. Catalano has over 30 years of experience serving clients principally in the fields of healthcare and life sciences. He assists private and public companies at various stages of development from early start-up to large multinational companies. He advises companies on SEC disclosures including IPOs, due diligence and complex accounting matters. Mr. Catalano has been involved with NewYorkBIO for over 25 years. He serves on the corporate advisory board of the Dolan DNA Learning Center and on the board of directors of Farmingdale College Foundation. Mr. Catalano is member of American Institute of Certified Public Accountants, New York State Society of CPA’s, and the Healthcare Financial Management Association. He received his BBA in accounting from Hofstra University.


Hans Christinger

Hans Christinger is Vice President of Business Development & Alliance Management at Ovid Therapeutics. Hans is a dedicated leader, innovator and advocate in the rare disease community with over 25 years of experience in the biopharmaceutical industry. At Ovid, Hans establishes and manages global strategic partnerships to rapidly bring potential therapeutics to patients and families affected by rare, neurological disorders, such as Ovid’s relationships with Takeda and Lundbeck. Hans is driven by hope and passion to increase awareness and advance a scientific understanding for members of the rare disease community. Hans plays a critical role in bringing together multiple stakeholders to efficiently address the unmet therapeutic needs within rare and neglected disease communities. Hans has led and executed numerous transactions for Ovid, Ophthotech, Abbott, Roche and Vertex. Having been based both in the US and abroad, he established and led teams to enable global, regional and local transactions across more than 30 countries in emerging and developed markets. Hans is an active board member and advisor to the KIF1A Foundation, NYBIO and several early-stage biotechnology companies. Hans began his career as a bench scientist at Genentech where he authored 15 structural biology related peer-reviewed papers. He earned a Master of Business Administration from Babson College, a Master of Science in Chemistry from San Francisco State University and a Bachelor of Science in Biochemistry from the University of Vermont.


Ellen Corenswet, Esq.

Ellen is a corporate lawyer with over 40 years of experience representing companies--from early stage to public—as well as investors in the life sciences and technology industries. Ellen also advises pharma venture capital organizations in their investments in life sciences companies. She is resident in the firm’s New York office. Ellen is passionate about working with founders and management teams in early stage companies and takes a hands-on, pragmatic, business-focused approach to advising these companies as their outside corporate general counsel. In addition to providing day-to-day strategic advice, Ellen advises on financings, corporate governance, employment and equity compensation issues, commercial agreements, IPOs, and M&A transactions. Ellen serves on the Council of National Advisors of Springboard Enterprises, Inc., and has been a long-time advisor to Springboard companies in the life sciences and technology sectors. Ellen is recognized as a leading life sciences corporate lawyer by The Practical Law Company (PLC) and is a frequent speaker on legal panels and at conferences.


Robert Easton

Bob Easton is Co-Chairman of Bionest Partners, an international consulting firm. For over 35 years, Bob Easton has been recognized as a leader in healthcare business consulting. He has built and led top firms, including The Wilkerson Group and Easton Associates. He has led scores of market development and strategic advisory assignments for clients, including large and specialty pharmaceutical companies, early-stage through publicly traded biopharmaceutical companies, and diagnostics businesses. He has influenced the decision-making of numerous healthcare professionals and supported hundreds of client executives in Australia, Japan, Canada, U.S., Europe and Israel. His interest in healthcare began when he managed a medical diagnostics business for Union Carbide. His education includes an MBA from Harvard Business School and engineering degrees from Rice University.


Jenna Foger

Jenna Foger is a Senior Vice President on Alexandria’s Science & Technology team, which provides scientific expertise and strategic industry insights to support the company’s real estate operations, venture investments, thought leadership, and business development initiatives. In her role, she leads venture investment activities and other ecosystem initiatives for Alexandria’s New York City life science cluster, most recently spearheading the strategic planning of Alexandria LaunchLabs, NYC’s premier startup life science platform, as well as the Alexandria Seed Capital Platform. Prior to joining Alexandria, Ms. Foger worked as an Associate at Windham Venture Partners, a boutique healthcare venture capital firm focused on growth-stage medical device, diagnostic, and digital health investments, where she assisted in growing the fund’s life science investment practice. Before Windham, she was a Senior Consultant at Navigant Consulting (formerly Easton Associates), a leading NYC-based healthcare consulting firm specializing in new product evaluation and strategic planning for companies across the life science industry. Ms. Foger also obtained extensive laboratory experience as a Neurobiology Research Associate at The Rockefeller University. She earned her master’s in Biotechnology from Columbia University and graduated Phi Beta Kappa summa cum laude from the University of Pennsylvania with a BA in Cognitive Neuroscience and Psychology.


Leena Gandhi

Dr. Gandhi graduated from the NYU School of Medicine and completed her fellowship at Dana-Farber Cancer Institute (DFCI). She worked in the Early Drug Development Center at DFCI and in the Thoracic Oncology Program as the Head of Clinical Trials until 2016, at which point she joined NYU Perlmutter Cancer Center as the Director of Thoracic Medical Oncology. She has worked on Phase 1, 2 and 3 trials of novel targeted therapies and immunotherapies in lung cancer, with a focus on evaluating potential biomarkers of response. She has been a lead investigator in clinical trials that helped define the use of PD-L1 as a biomarker of response to PD-1 inhibition in non-small cell lung cancer. Dr. Gandhi most recently served as the lead investigator on the KEYNOTE-189 study, published in theNew England Journal of Medicine in April 2018. This study demonstrated an improved survival rate with the addition of pembrolizumab to pemetrexed and platinum chemotherapy for patients with recurrent lung cancer.


Martin Graham


Karen Heidelberger

As Chief Partnership and Communications Officer at Deerfield, Karen is responsible for relationships with investors, partner companies, and other interested parties. Prior to this role, Karen was a Trader at Deerfield for over a decade. In this capacity, she was responsible for trading in public securities on behalf of the Funds and developing and communicating market information to the firm. Prior to joining Deerfield in 2002, Karen was a Vice President in the Sales and Trading division of Merrill Lynch. Also at Merrill, she served as a Conflicts Coordinator in the Mergers and Acquisitions department. In this role she was responsible for ensuring that Merrill Lynch was clear of legal and business conflicts of interest before the firm was able to accept an assignment. Karen is on the board of the Cornell Institute for Healthy Futures since 2016. She graduated from the Cornell University, School of Hotel Administration and earned her M.B.A. from Harvard Business School.


David Lechner

David Lechner is currently the Area Vice President for VWR, part of Avantor. In his current role, he has commercial responsibility for all Pharmaceutical, Biotechnology and Industrial businesses within the Mid-Atlantic and Northeast Area. Mr. Lechner has over 25 years of experience in the pharmaceutical and biotechnology sector. Prior to assuming his current position, Mr. Lechner held the position of VWR’s Vice President, Strategic Partners, managing global customer relationships for VWR’s largest Pharmaceutical customers. In addition, Mr. Lechner has served as the President of the Hemophilia Association of New Jersey, July 2016 – June 2018, working with members of the Biopharma Industry to bring programs and assistance to members of the Hemophilia community. Mr. Lechner still currently serves on the Board of Director for the Hemophilia Association on New Jersey.


Todd Little

Todd Little serves as Executive Director at Transnetyx, as well as Executive Advisor for Thompson Street Capital Partners. He was previously President at Taconic Biosciences. A Taconic employee since 1991, Little has 30 years of experience in the development and production of in vivo models and services for drug discovery and pre-clinical investigations. During his tenure at Taconic, he spearheaded Taconic’s diversification into technical services and led the geographic expansion of the company into Denmark, Germany, California and Indiana. He also serves on the Transnetyx Board of Directors and was a founding member and previous Chair of Bioconnex, an Albany NY life sciences networking group.


Sharon Mates, PhD

Sharon Mates has been the Chairman of the board of directors, President and Chief Executive Officer of Intra-Cellular Therapies since June 2002. Dr. Mates co-founded ITI in May 2002. Prior to co-founding ITI, Dr. Mates was a co-founder of Functional Genetics, and served as its Chairman and Chief Executive Officer from December 2000 until August 2003. From 1989-1998, Dr. Mates was the President and a board member of North American Vaccine Inc. and its predecessor companies. She has served on several boards, and recently completed a board membership and a two-year chairmanship of the Board of the New York Biotechnology Association. Dr. Mates has also served on the Advisory Council of the Center for Society and Health at the Harvard School of Public Health, the Board of Visitors of the Biotechnology Institute of the University of Maryland, and the board of directors of Gilda’s Club of New York. Earlier in her career, Dr. Mates spent several years as a research analyst and investment banker, and as an advisor to the life sciences industry. Dr. Mates received her B.S. from the Ohio State University and her Ph.D. from the University of Washington, and completed her postdoctoral fellowships at The Massachusetts General Hospital and Harvard Medical School.


Kate Merton

As Head of Johnson & Johnson Innovation, JLABS in New York, Kate is responsible for external engagement, innovation sourcing, company onboarding, portfolio management, operational excellence, educational programming and P&L. She catalyzes and supports the translation of science and technology into valuable solutions for patients and consumers across the pharmaceutical, medical device, consumer and healthtech sectors. Kate joins JLABS with 15 years of experience working across the Healthcare industry, starting in R&D before moving onto roles in Marketing, Business Development, External Alliances, Medical Affairs, Health Outcomes and most recently Disruptive Innovation. During her career Kate has been part of teams that have discovered new drugs, worked to develop and gain approval for blockbuster diabetes products and is passionate about being part of the future of healthcare where science intersects with the rapid advancements in health care technology. Kate holds an undergraduate degree in Pharmacology & Toxicology from King’s College London, and a PhD in Pharmacology & Toxicology from University of California, Irvine Medical School. She received her MBA from the Fuqua School of Business at Duke University.


Hala Mirza

Hala Mirza is the Vice President, Corporate Communications and Citizenship at Regeneron, a leading science-driven biotechnology company. At Regeneron, Mirza leads corporate citizenship, philanthropy, employee volunteerism, internal and external communications, product communications and community relations. Mirza’s team manages all of Regeneron’s STEM education and outreach programs including the Regeneron Science Talent Search, the nation’s most prestigious high school science talent competition. The company also has a number of long-term, impact-focused regional science education initiatives. Mirza joined Regeneron from Pfizer, where she was the VP, Corporate Affairs for R&D and Strategy. In this role, Mirza drove an internal and external campaign that reshaped the conversation around Pfizer as a science and innovation leader. Prior to joining Pfizer, Mirza was Managing Director, W20 group, a leading healthcare integrated communications agency, where she played a key role in driving the agency’s tremendous growth over eight years. Previously in her career, Mirza served as Public Relations Officer at the American Red Cross Biomedical Services. Mirza is a member of the Healthcare Businesswomen’s Association and the Arthur W. Page Society. She holds a BA in English Literature from The George Washington University, where she was a Tip O’Neil Scholar.


Timothy O'Connor, PhD

Timothy O’Connor was appointed executive vice president of The Rockefeller University in February 2016. In this role, he oversees most university operations, including research support, technology transfer, facilities, and information technology, as well as finance, investments, human resources, and legal affairs. Working in partnership with the other executive officers, he provides administrative leadership to the university and represents the president both internally and externally. He originally joined the university in 2013 as chief of staff and vice president. Dr. O’Connor’s career has focused on both biomedical research and academic administration. Most recently, he served as associate provost for science and technology at Yale University; prior to that, he was associate research professor and vice chair in the Department of Genetic Medicine at Weill Cornell Medical College. He currently serves on the boards of the New York Structural Biology Center, the Aaron Diamond AIDS Research Center, and Friends of the East River Esplanade.


Joel Papernik

Joel Papernik is partner at Mintz Levin.  Joel concentrates on corporate, commercial, and securities matters as well as strategic transactions and corporate structuring. He is a member of the firm’s Opinions Committee and has also served as a member of the firm's Policy Committee.He has extensive experience counseling high-technology businesses and the individuals creating them. He frequently guides acquisitions, collaborations, and licensing transactions in the life sciences industry. As more life sciences companies have extended their activities from discovery to development, his practice has been more involved with development and later stage activity.



Prem Premsrirut, PhD

Dr. Premsrirut is CEO of Mirimus and  an expert in the development and use of RNAi transgenic mice. She was an inventor of technological advancements that lead to the development of a high-throughput platform for rapid and efficient generation of conditional RNAi transgenic mice. She pioneered a novel approach for the generation of "speedy” chimeric GEMMs based on rederivation of mouse embryonic stem cells (ESCs) from existing mouse strains with a predisposition to cancer.  Dr. Premsrirut received a Ph.D. in genetics following her training in the laboratory of Dr. Scott Lowe at Cold Spring Harbor Laboratory.


Dennis Purcell

Dennis is Founder and Senior Advisor at Aisling Capital. During his tenure, Dennis has been directly involved with over two hundred completed transactions and supervised over $15 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist). Dennis is a frequent commentator on the industry and has been honored in various publications as a top contributor to the Life Sciences Industry. He sits on numerous private and public healthcare company boards, such as Real Endpoints and Summus Global. He is actively involved with many of the industry’s professional organizations. He is Executive Chairman of Poliwogg Holdings, a company devising new financed products for the healthcare industry. Dennis received his M.B.A. from Harvard University and his B.S. in Accounting from the University of Delaware.


Lily Safani

Lily Safani has served as the CEO of Gilda’s Club NYC (GCNYC) since February 2007. GCNYC is a non-profit organization whose mission is to support, educate and empower cancer patients and their families in New York City – free of charge. Gilda’s Club believes that no one should face cancer alone. Their comprehensive cancer program is a complement to medical treatment and includes support and networking groups, educational lectures, and healthy lifestyle workshops for everyone impacted by cancer – men, women, teens and children – in a beautiful Clubhouse in the West Village and at hospital partners throughout New York City. Each year Gilda’s Club reaches over 20,000 New Yorkers living with cancer. With over 39,000 New Yorkers newly diagnosed with cancer each year, there is an unmet need to provide a comprehensive cancer support resource to help individuals learn to live with cancer whatever the outcome. Lily moved to Gilda’s Club from Continuum Hospice Care, a subsidiary of Continuum Health Partners and the largest hospice in New York City. As the Senior Vice President of Business Development, she was responsible for strategic planning, business development and human resources. She directed efforts to successfully increase the patient census and market penetration throughout the city by developing new partnerships with NYC hospitals, nursing and assisted living facilities in the five boroughs. From 2002 to 2005, Lily served as the Vice President of Development, Marketing and Public Relations for North General Hospital, the only private, not-for-profit hospital in the underserved Harlem community. During her time there, Lily established a development and marketing infrastructure, formulated and began implementing a 5-year business plan to meet fundraising goals and engaged the Board of Directors in fundraising for the first time. She was instrumental in securing over $2.5 million in donations in less than 2 years, establishing an effective public relations program to increase their visibility, and promoting the hospital and its services throughout Harlem. In 2002, Lily switched from financial services to the non-profit healthcare sector, motivated to use her for-profit experience to make a difference wherever she could, particularly in the underserved communities of New York City. Her first experience in healthcare increased her awareness of the tremendous disparities in medical care within low income communities as evidenced by their poorer outcomes and higher mortality rates across almost all chronic illnesses. From 1989 to 2002, Lily served as Founder and President of Safani Direct Inc., a successful direct marketing agency, specializing in new business development and marketing for the financial services industry. Among her clients were the Northeast’s leading financial institutions including Citi, MasterCard International and JPMorganChase. Prior to founding her company, she worked at Tempest & Safani (1984-1988), Benton & Bowles Direct (1981-1984) and Citicorp (1977-1981) specializing in strategic planning, new product development, direct marketing and branding for the financial services and computer technology industries. Lily holds a BA from Barnard College, an MBA from the Wharton Graduate School of Business, and has completed Harvard Business School Strategic Perspectives in NonProfit Management. She also serves on the board of NYBIO. Outside of work, she and her husband, Dr. Jeffrey Friedman, spend time with their twin daughters, Nathalie and Alexandra, enjoying the beach, travel, New York City and their individuality.


Joseph Scaduto

Mr. Scaduto is the Founder and CEO of Traverse Biosciences, an emerging bioscience company commercializing a proprietary library of novel drug candidates to treat chronic inflammatory conditions affecting humans and animals. Mr. Scaduto has also served as BioEntrepreneur-In-Residence (B-EIR) at the Center for Biotechnology at Stony Brook University. Mr. Scaduto was previously the Assistant Director of Business Development at the Center for Biotechnology, as well as the founding Executive Director of the Long Island Life Sciences Initiative (LILSI), where he helped launch the annual Life Sciences Summit. He has over 15 years of experience providing business development expertise, strategic planning services and technology commercialization guidance to emerging and expanding bioscience companies on Long Island and throughout New York State. Mr. Scaduto previously served on the Tenant Selection and Review Committee of the Stony Brook University Incubator Program, including the Long Island High Technology Incubator (LIHTI), and was Chair of the Bioscience Screening Committee of the Long Island Angel Network (LIAN). Mr. Scaduto was also an active member of the Economic Development Council at Stony Brook University, the Advisory Board of the Clean Energy Business Incubation Program (CEBIP), the Selection Committee of the annual Long Island Technology Hall of Fame, and the Advisory Committee of the Long Island Index produced annually by the Rauch Foundation. Mr. Scaduto holds a BS in Biology from Binghamton University, a MS in Biotechnology from Northwestern University, and a MBA in Finance from Stony Brook University.


Arthur Tinkelenberg, PhD

Dr. Arthur H. Tinkelenberg, PhD is former President and Chief Executive Officer of Enumeral Biomedical Corporation. Dr. Tinkelenberg previously served as a Partner of Ascent BioMedical Ventures (ABV). Prior to joining ABV, Dr. Tinkelenberg worked in the Healthcare Investment Banking and Mergers and Acquisitions Groups at Robertson Stephens. He has served as a Director of a number of companies, and is currently an Advisor to Torreya, a strategic advisory firm focused on the biotechnology and pharmaceutical sectors. Dr. Tinkelenberg earned his Ph.D. degree in Molecular Genetics from The Rockefeller University where he studied cell growth regulation and signal transduction as a Rockefeller and National Science Foundation Fellow and earned his BA degree in Biology, with honors, from Grinnell College.